Eating Disorders · Texas behavioral health news
USPTO Issues Foundational Patent for Leptin Replacement in Anorex - The National Law Review
Eating Disorders (Google News) · August 11, 2026
In plain language
Researchers have received a new patent for using leptin replacement to treat anorexia nervosa. Scientists believe that a lack of leptin, a hormone related to body fat, may actually drive the symptoms of anorexia rather than just being a result of weight loss. While the FDA has not yet approved this treatment for anorexia, a pharmaceutical company is now working to design clinical trials to test its safety and effectiveness. This could eventually lead to the first government-approved medication specifically for this eating disorder.
AI-generated summary of the source article. Not medical advice.
Key takeaways
- A new patent protects the use of leptin replacement therapy for treating anorexia until 2045.
- Researchers suggest leptin deficiency is an active driver of anorexia symptoms rather than a side effect.
- Zula Therapeutics is collaborating with Mount Sinai to design clinical trials for the treatment.
- Currently, there are no FDA-approved medications specifically for anorexia nervosa.
- A randomized controlled trial for this treatment is currently underway and expected to finish enrollment in 2026.
USPTO Issues Foundational Patent for Leptin Replacement in Anorex The National Law Review
Need to talk to someone in Texas? Browse Texas-licensed telehealth therapists. In crisis, call or text 988.